Aernoud T.L. Fiolet

Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT

Jalina Jannink, Aimee van Zelm, Soumaya Chemlal, Fabrice MAC Martens et autres

nl (code pays fourni par la source)

Allopurinol, gout, and cardiovascular risk

Jalina Jannink, Arend Mosterd, Aernoud T.L. Fiolet

Jalina Jannink, Arend Mosterd, Aernoud T L Fiolet; Allopurinol, gout and cardiovascular risk, European Journal of Preventive Cardiology, , zwaf696, https:/

nl, de (code pays fourni par la source)

Current Evidence and Future Directions for Colchicine in the Prevention of Atherosclerotic Cardiovascular Disease

Aimée Marjolijn Healey van Zelm, Aernoud T.L. Fiolet, Robert J. Hinchliffe, Shirley Jane Jansen et autres

Chronic inflammation plays a key role in the development and progression of atherosclerotic cardiovascular disease (ASCVD) and its complications. Despite the use of blood pressure-, lipid-, and glucose-lowering therapies as well as antithrombotic agents, the lifetime residual cardiovascular (CV) risk in patients …

nl, gb, au, ca (code pays fourni par la source)

Type A Aortic Dissection of the Donor Aorta After Heart Transplantation

Sven Geurts, Aernoud T.L. Fiolet, Marish I.F.J. Oerlemans, Ronald C. A. Meijer et autres

Type A aortic dissection (TAAD) is a rare, but potential lethal complication post-heart transplantation (HTx) that typically affects the native aorta. This case report describes a supracoronary ascending aortic replacement in a patient who was admitted with a TAAD of the donor …

nl (code pays fourni par la source)

Response commentary: the effect of colchicine on coagulation in patients with chronic coronary disease who use vitamin K antagonists

Jeroen P. A. Houwen, Arief Lalmohamed, Toine C. G. Egberts, Michiel Duyvendak et autres

nl (code pays fourni par la source)

Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis

Niekbachsh Mohammadnia, Liying Xue, Lucas T W Vestjens, Md Mesbah Uddin et autres

BACKGROUND: Clonal hematopoiesis (CH) is an aging-related hematologic condition associated with increased risk for cardiovascular events. Larger CH clones associate more strongly with cardiovascular risk. Preclinical data indicate that inflammatory signaling drives expansion of CH clones and CH-associated cardiovascular disease. However, the …

nl, us, it, ca (code pays fourni par la source)

Colchicine for secondary prevention of vascular events: a meta-analysis of trials

Marc-André d'Entremont, Michiel H.F. Poorthuis, Aernoud T.L. Fiolet, Pierre Amarenco et autres

BACKGROUND AND AIMS: Randomized trials of colchicine in secondary prevention of atherosclerotic cardiovascular disease have shown mixed results. METHODS: A systematic review and study-level meta-analysis of randomized controlled trials was performed comparing colchicine vs no colchicine in a secondary-prevention atherosclerotic cardiovascular disease …

Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial

Niekbachsh Mohammadnia, Britta E. Wesselink, Willem A. Bax, Stefan Mark Nidorf et autres

Background The LoDoCo2 (Low‐Dose Colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events in patients with chronic coronary syndrome. Current guidelines recommend colchicine use in selected high‐risk patients. The aim of this secondary analysis was to explore the relative …

nl, us, au, ca (code pays fourni par la source)

Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort

Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A. Bax, John W. Eikelboom et autres

Background and aims There is a need for effective tools to stratify and modify cardiovascular risk associated with elevated lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPL). The objective of this analysis was to explore the modifying effects of low-grade inflammation on Lp(a)- and …

nl, us, ca, au (code pays fourni par la source)

Colchicine for secondary prevention of vascular events: a meta-analysis of trials

Marc-André d’Entremont, Michiel H.F. Poorthuis, Aernoud T.L. Fiolet, Pierre Amarenco et autres

BACKGROUND AND AIMS: Randomized trials of colchicine in secondary prevention of atherosclerotic cardiovascular disease have shown mixed results. METHODS: A systematic review and study-level meta-analysis of randomized controlled trials was performed comparing colchicine vs no colchicine in a secondary-prevention atherosclerotic cardiovascular disease …

ca, nl, jp, be, us, au, mk, fr, es, cn, ie (code pays fourni par la source)

The effect of colchicine on coagulation in patients with chronic coronary disease who use vitamin K antagonists

Jeroen P. A. Houwen, Arief Lalmohamed, Toine C. G. Egberts, Michiel Duyvendak et autres

BACKGROUND: Low-dose (0.5 mg/day) colchicine improves cardiovascular outcomes in patients with stable coronary disease. Around 10-15% of these patients simultaneously use anticoagulant therapy, including vitamin-K antagonists (VKAs). In vitro studies and case reports have described a possible interaction between colchicine and VKAs …

nl (code pays fourni par la source)

Sex Differences in Permanent Discontinuation of Trial Medication in Chronic Coronary Artery Disease: The LoDoCo2 Trial

Marte F. van der Bijl, J. Van der Veen, Aernoud T.L. Fiolet, Eric H. Boersma et autres

Contains fulltext : 317506.pdf (Publisher’s version ) (Open Access)

nl, us, gr, ca, au (code pays fourni par la source)